Clinical trials: Pancreatic Fibrosis
Cystic Fibrosis
Efficacy and Safety Study of EGCG/Tocotrienol in 18 Patients With Splicing-mutation-mediated Cystic Fibrosis (CF)
Working Hypothesis: EGCG and Tocotrienol can act as genetic modifiers and increase the level of correctly spliced CFTR transcripts.
- Trial name
- NCT00889434
- Testing
- ECGC, Tocotrienol, EGCG + Tocotrienol
- Where
- Israel
- Volunteers
- 7 people
- Sponsor
- Hadassah Medical Organization
Pancreatitis, Acute Pancreatitis
Fibro-inflammatory Progression From Acute to Chronic Pancreatitis
Observational prospective study evaluating the developement of chronic pancreatitis based on imaging modalities as well as biochemical markers of inflammation, fibrosis and oxidative stress.
- Conditions
- Pancreatitis, Acute Pancreatitis, Recurrent Pancreatitis, Chronic Pancreatitis
- Trial name
- NCT03853447
- Testing
- Diagnostic imaging
- Where
- 3 sites in Denmark
- Volunteers
- 150 people
- Sponsor
- Copenhagen University Hospital, Hvidovre
Cystic Fibrosis-related Diabetes, Cystic Fibrosis
Continuous Glucose Monitoring and OGTT Screen for Cystic Fibrosis Related Diabetes in Cystic Fibrosis
Cystic Fibrosis (CF) related diabetes (CFRD) is a unique form of diabetes mellitus, different from type 1 diabetes and type 2 diabetes.
- Trial name
- NCT06560463
- Testing
- Access to Dexcom G7 CGM Data
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Medical College of Wisconsin
Cystic Fibrosis
Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation
The purpose of this study is to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis (CF) who have a non-G551D cystic fibrosis transmembrane regulator (CFTR) gating mutation (any one of the following…
- Trial name
- KONNECTION (NCT01614470)
- Testing
- Ivacaftor
- Where
- 12 sites in United States, Belgium and 1 more
- Volunteers
- 39 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Pulmonary Cystic Fibrosis, Neutralizing Antibodies
Characterization of Antibacterial Antibodies in Patients With Cystic Fibrosis
Most of the cystic fibrosis (CF) patients are or have been pulmonary colonized with bacteria such as Pseudomonas aeruginosa or Staphylococcus aureus.
- Trial name
- NCT04700358
- Testing
- Blood sampling
- Where
- Germany
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University Hospital of Cologne
Cystic Fibrosis, Periodontitis
Cystic Fibrosis and Periodontal Diseases
The number of CF adults is increasing year after year (61.7% in 2021) confirming that patients are living longer. These data do not leave aside the desire to see CF patients "age well" considering of all the comorbidities linked…
- Conditions
- Cystic Fibrosis, Periodontitis, Gingivitis
- Trial name
- MucoParo (NCT06133335)
- Testing
- Periodontal examination
- Where
- France
- Volunteers
- 50 people
- Sponsor
- CHU de Reims
Cystic Fibrosis, Colorectal Cancer
Colorectal Cancer Screening in Cystic Fibrosis
This multi-center study will compare multi-target DNA and quantitative FIT stool-based testing to colonoscopy in individuals with Cystic Fibrosis (CF) undergoing colon cancer screening with colonoscopy.
- Conditions
- Cystic Fibrosis, Colorectal Cancer, Adenoma
- Trial name
- NICE-CF (NCT05362344)
- Testing
- Stool tests
- Where
- 26 sites in United States
- Volunteers
- 350 people
- Sponsor
- University of Washington, the Collaborative Health Studies Coordinating Center
Cystic Fibrosis
Study of Hepatic Glucose Production and De Novo Lipogenesis in Patients With Cystic Fibrosis
OBJECTIVES: I. Determine the amount of hepatic glucose production derived from gluconeogenesis and glycogenolysis in the post-absorptive state in patients with cystic fibrosis. II.
- Trial name
- NCT00014781
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- University of Utah
Cystic Fibrosis
A Study to Evaluate Safety, PK and PD of FDL169 in Cystic Fibrosis Subjects
This is a multicenter, randomized, placebo-controlled, dose-escalation study. Enrollment is planned to occur at approximately 14 global sites. Approximately 24 subjects with CF.
- Trial name
- NCT03093714
- Testing
- FDL169
- Where
- 14 sites in Australia, Czechia and 2 more
- Volunteers
- 27 people
- Sponsor
- Flatley Discovery Lab LLC
Cystic Fibrosis
NPD Measurement in Infants
Nasal Potential Difference measurements (NPD) have been performed in Israel since 1996. NPD measurements are used to assess the voltage across nasal epithelium, which correlates with the transport of sodium and chloride across…
- Trial name
- NCT00564304
- Volunteers
- 50 people
- Sponsor
- Hadassah Medical Organization
Cystic Fibrosis
A Study to Investigate the Safety and Tolerability of Single and Multiple Ascending Doses of KIT2014 in Healthy Subjects
This is the first-in-human study with KIT2014 designed to provide safety, tolerability and pharmacokinetic data in healthy volunteers.
- Trial name
- NCT06659757
- Testing
- KIT2014
- Where
- Australia
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Kither Biotech Srl
Cystic Fibrosis
Urinary and Anorectal Functional Disorders and Their Impact on CF Adults (PerineoMucoRMO)
This observational study evaluates prevalence of functional perinea disorders (stress urinary incontinence, overactive bladder syndrome, dysuria, anal incontinence) on CF adults patients of the North-West CF Network.
- Trial name
- PerineoMuco (NCT02894619)
- Where
- 6 sites in France
- Volunteers
- 180 people
- Sponsor
- Fondation Ildys
Cystic Fibrosis
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation
The purpose of this study was to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis aged 12 years and older who have the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR)…
- Trial name
- STRIVE (NCT00909532)
- Testing
- Ivacaftor
- Where
- 65 sites in United States, Australia and 6 more
- Volunteers
- 167 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Adrenal Hyperplasia, Congenital, Congenital Hypothyroidism
Clinical Evaluation of NeoPlex4 Assay and NeoPlex System
The purpose of this study is to assess the agreement of clinical performance between the proposed NeoPlex 4 assay and NeoPlex System and the comparator devices in clinical use in newborn screening programs for detection of T4…
- Conditions
- Adrenal Hyperplasia, Congenital, Congenital Hypothyroidism, Cystic Fibrosis
- Trial name
- NCT01488721
- Where
- 3 sites in United States
- Volunteers
- 7,462 people, healthy volunteers welcome
- Sponsor
- Luminex Corporation
Cystic Fibrosis
Clinical Effects of Exercise Program Added to Pulmonary Rehabilitation in Patients With Cystic Fibrosis
The aim of this study is to investigate the effects of postural exercise program added to pulmonary rehabilitation program on quality of life, exercise tolerance and postural stability in children with Cystic Fibrosis.
- Trial name
- NCT03295201
- Testing
- Active cycle of breathing techniques (ACBT), Postural Exercise
- Where
- Turkey (Türkiye)
- Volunteers
- 22 people
- Sponsor
- Marmara University
Cystic Fibrosis
Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI)
The purpose of this interventional Phase IV study was to explore the ease of use of TIP and prevalence of microbial contamination of the T-326 Inhaler compared with TIS and colistimethate administered via nebuliser for the…
- Trial name
- NCT01844778
- Testing
- Tobramycin Inhalation Powder, Tobramycin inhalation solution, Colistimethate
- Where
- 21 sites in Germany, Ireland and 3 more
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Cystic Fibrosis - Complete
Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators.
The goal of this clinical trial is to evaluate the safety and tolerability of TMX in adults patients with cystic fibrosis who do not have mutations currently eligible for therapy with modulator drugs.
- Trial name
- TMX (NCT07289035)
- Testing
- Tamoxifen Citrate 20Mg Tab
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Hearing Loss, Sensorineural, Cystic Fibrosis
A Study of Web and Tablet-based Interactive Audiometry in Adults With CF
Adults with CF regularly receive anti-infective therapy that can result in impaired hearing. Recent studies have identified that up to 50% of adults with CF have hearing loss with resulting significant impact on quality of life.
- Trial name
- NCT04400955
- Testing
- Audiometry tablet diagnostic tool and web-based test
- Where
- United Kingdom
- Volunteers
- 156 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Cystic Fibrosis
Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients
The purpose of this actual use human factors (HF) study is to validate the approved US TOBI Podhaler Instructions for Use (IFU), by establishing that the IFU effectively communicates the information necessary to achieve safe and…
- Trial name
- NCT02178540
- Testing
- Tobi Podhaler
- Where
- 13 sites in United States
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Cystic Fibrosis
Vitamin K Supplementation to Reduce Deficiencies in Adults With Cystic Fibrosis
Cystic fibrosis (CF) patients are at risk for vitamin K deficiencies. Supplementation for fat-soluble vitamins A, D, and E is well established, but in CF, there is little data for vitamin K concerning the optimal dose and…
- Trial name
- VITK-FK (NCT04496921)
- Testing
- Vitamin K supplementation, dose #1, Vitamin K supplementation, dose #2
- Where
- 2 sites in Canada
- Sponsor
- Institut de Recherches Cliniques de Montreal
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.